RPRX

SEC source: 0001209191-22-058450 · doc4.xml · nonDerivative · entry 3

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 130,000

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.30 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-058450 · doc4.xml · nonDerivative · entry 2

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 351,900

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.20 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-058450 · doc4.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 144,469

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.20 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-058252 · doc4.xml · nonDerivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,712

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.16 to $42.53 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-056677 · doc4.xml · nonDerivative · entry 2

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 355,000

F1 · shares: Class A Ordinary Shares sold pursuant to a 10b5-1 plan.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.65 to $43.94 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-056677 · doc4.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 165,000

F1 · shares: Class A Ordinary Shares sold pursuant to a 10b5-1 plan.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.64 to $43.95 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-056420 · doc4.xml · nonDerivative · entry 1

Coyne Terrance P. · CIK 0001814876 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Indirect · By TPC RP 2021, LLC

Disclosed balance after: 940,000

F1 · kind: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.85 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.85 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-055873 · doc4.xml · nonDerivative · entry 1

Coyne Terrance P. · CIK 0001814876 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Indirect · By TPC RP 2021, LLC

Disclosed balance after: 964,500

F1 · kind: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.17 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.17 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-051644 · doc4.xml · nonDerivative · entry 1

Bassler Bonnie L · CIK 0001683607 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,838

F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

SEC source: 0001209191-22-051640 · doc4.xml · nonDerivative · entry 1

Fernandez Henry A · CIK 0001416750 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,044

F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

SEC source: 0001209191-22-051637 · doc4.xml · nonDerivative · entry 1

Reddoch James F. · CIK 0001814872 · EVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Reddoch RPI LLC

Disclosed balance after: 820,800

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.03 to $41.57 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001140361-22-035474 · form4.xml · nonDerivative · entry 1

Giuliani Mario Germano · CIK 0001814882 · Director · 10% owner

Skyeline Management Ltd · CIK 0001814877 · 10% owner

Avara Management Ltd · CIK 0001814934 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 8,077,140

F1 · ownership.nature: Reflects securities held directly by Skyeline Management Ltd. Skyeline Management Ltd is wholly-owned by Avara Management Ltd. Avara Management Ltd is wholly-owned by M. Germano Giuliani.

F2 · ownership.nature: Each of the Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the direct holder to the extent of its direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein or are subject to Section 16.

SEC source: 0001140361-22-034705 · form4.xml · nonDerivative · entry 1

Giuliani Mario Germano · CIK 0001814882 · Director · 10% owner

Skyeline Management Ltd · CIK 0001814877 · 10% owner

Avara Management Ltd · CIK 0001814934 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 8,109,733

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.36 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.nature: Reflects securities held directly by Skyeline Management Ltd. Skyeline Management Ltd is wholly-owned by Avara Management Ltd. Avara Management Ltd is wholly-owned by M. Germano Giuliani.

F2 · ownership.nature: Each of the Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the direct holder to the extent of its direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein or are subject to Section 16.

SEC source: 0001140361-22-034416 · form4.xml · nonDerivative · entry 3

Giuliani Mario Germano · CIK 0001814882 · Director · 10% owner

MGG Strategic SICAF SIF S.A. - MGG Strategic · CIK 0001814889 · 10% owner

MGG Strategic SICAF SIF S.A. · CIK 0001922189 · 10% owner

Skyeline Management Ltd · CIK 0001814877 · 10% owner

Avara Management Ltd · CIK 0001814934 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 8,321,113

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.545 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.nature: Each of the Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the direct holder to the extent of its direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein or are subject to Section 16.

F3 · ownership.nature: Reflects securities held directly by Skyeline Management Ltd. Skyeline Management Ltd is wholly-owned by Avara Management Ltd. Avara Management Ltd is wholly-owned by M. Germano Giuliani.

SEC source: 0001140361-22-034414 · form4.xml · nonDerivative · entry 1

GG 1978 SICAF SIF S.A. - GG Strategic · CIK 0001814890 · 10% owner

GG 1978 SICAF SIF S.A. · CIK 0001814891 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 21,426,170

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.61 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.nature: Reflects securities held directly by GG 1978 SICAF SIF S.A. - GG Strategic ("GG Strategic").

F2 · ownership.nature: GG Strategic is a sub-fund managed and administered by GG 1978 SICAF S.A. ("GG 1978 SICAF"). A board of directors consisting of Giammaria Giuliani, Achille G. Severgnini, Marco Sterzi and Franco Toscano has voting and dispositive power over the securities managed by GG 1978 SICAF. Each member of the board disclaims beneficial ownership over such shares. GG 1978 SICAF is owned by the GG Trust, of which Giammaria Giuliani is the beneficiary. The GG Trust is the 100% economic owner of the shares held by GG Strategic. Giammaria Giuliani disclaims beneficial ownership over the shares beneficially owned by GG Strategic. The trustee of the GG Trust is GISEV Trustees Limited. The protector of the GG Trust is Achille G. Severgnini, who has the power to remove and replace the trustee of the GG Trust.

F3 · ownership.nature: Each of the Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the direct holder to the extent of its direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein or are subject to Section 16.

SEC source: 0001140361-22-034416 · form4.xml · nonDerivative · entry 2

Giuliani Mario Germano · CIK 0001814882 · Director · 10% owner

MGG Strategic SICAF SIF S.A. - MGG Strategic · CIK 0001814889 · 10% owner

MGG Strategic SICAF SIF S.A. · CIK 0001922189 · 10% owner

Skyeline Management Ltd · CIK 0001814877 · 10% owner

Avara Management Ltd · CIK 0001814934 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 8,446,810

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.19 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.nature: Each of the Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the direct holder to the extent of its direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein or are subject to Section 16.

F3 · ownership.nature: Reflects securities held directly by Skyeline Management Ltd. Skyeline Management Ltd is wholly-owned by Avara Management Ltd. Avara Management Ltd is wholly-owned by M. Germano Giuliani.

SEC source: 0001140361-22-034416 · form4.xml · nonDerivative · entry 1

Giuliani Mario Germano · CIK 0001814882 · Director · 10% owner

MGG Strategic SICAF SIF S.A. - MGG Strategic · CIK 0001814889 · 10% owner

MGG Strategic SICAF SIF S.A. · CIK 0001922189 · 10% owner

Skyeline Management Ltd · CIK 0001814877 · 10% owner

Avara Management Ltd · CIK 0001814934 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 22,390,000

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.55 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.nature: Reflects securities held directly by MGG Strategic SICAF SIF S.A. - MGG Strategic, a Luxembourg company ("MGG Strategic"). MGG Strategic is a sub-fund managed and administered by MGG Strategic SICAF SIF S.A. ("MGG SICAF"). A board of directors consisting of M. Germano Giuliani, Achille G. Severgnini, Marco Sterzi and Franco Toscano has voting and dispositive power over the securities managed by MGG SICAF. Each member of the board disclaims beneficial ownership over such shares. MGG SICAF is owned by the MGG Trust of which M. Germano Giuliani is the beneficiary. The MGG Trust is the 100% economic owner of the shares held by MGG Strategic. M. Germano Giuliani disclaims beneficial ownership over the shares beneficially owned by MGG Strategic. The trustee of the MGG Trust is GISEV Trustees Limited. The protector of the MGG Trust is Achille G. Severgnini, who has the power to remove and replace the trustee of the MGG Trust.

F2 · ownership.nature: Each of the Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the direct holder to the extent of its direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein or are subject to Section 16.

SEC source: 0001140361-22-034011 · form4.xml · nonDerivative · entry 2

GG 1978 SICAF SIF S.A. - GG Strategic · CIK 0001814890 · 10% owner

GG 1978 SICAF SIF S.A. · CIK 0001814891 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 21,693,985

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.99 to $41.77 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.nature: Reflects securities held directly by GG 1978 SICAF SIF S.A. - GG Strategic ("GG Strategic").

F2 · ownership.nature: GG Strategic is a sub-fund managed and administered by GG 1978 SICAF S.A. ("GG 1978 SICAF"). A board of directors consisting of Giammaria Giuliani, Achille G. Severgnini, Marco Sterzi and Franco Toscano has voting and dispositive power over the securities managed by GG 1978 SICAF. Each member of the board disclaims beneficial ownership over such shares. GG 1978 SICAF is owned by the GG Trust, of which Giammaria Giuliani is the beneficiary. The GG Trust is the 100% economic owner of the shares held by GG Strategic. Giammaria Giuliani disclaims beneficial ownership over the shares beneficially owned by GG Strategic. The trustee of the GG Trust is GISEV Trustees Limited. The protector of the GG Trust is Achille G. Severgnini, who has the power to remove and replace the trustee of the GG Trust.

F3 · ownership.nature: Each of the Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the direct holder to the extent of its direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein or are subject to Section 16.

SEC source: 0001140361-22-034012 · form4.xml · nonDerivative · entry 2

Giuliani Mario Germano · CIK 0001814882 · Director · 10% owner

MGG Strategic SICAF SIF S.A. - MGG Strategic · CIK 0001814889 · 10% owner

MGG Strategic SICAF SIF S.A. · CIK 0001922189 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 22,657,815

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.995 to $41.79 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.nature: Reflects securities held directly by MGG Strategic SICAF SIF S.A. - MGG Strategic, a Luxembourg company ("MGG Strategic"). MGG Strategic is a sub-fund managed and administered by MGG Strategic SICAF SIF S.A. ("MGG SICAF"). A board of directors consisting of M. Germano Giuliani, Achille G. Severgnini, Marco Sterzi and Franco Toscano has voting and dispositive power over the securities managed by MGG SICAF. Each member of the board disclaims beneficial ownership over such shares. MGG SICAF is owned by the MGG Trust of which M. Germano Giuliani is the beneficiary. The MGG Trust is the 100% economic owner of the shares held by MGG Strategic. M. Germano Giuliani disclaims beneficial ownership over the shares beneficially owned by MGG Strategic. The trustee of the MGG Trust is GISEV Trustees Limited. The protector of the MGG Trust is Achille G. Severgnini, who has the power to remove and replace the trustee of the MGG Trust.

F2 · ownership.nature: Each of the Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the direct holder to the extent of its direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein or are subject to Section 16.

SEC source: 0001140361-22-034011 · form4.xml · nonDerivative · entry 1

GG 1978 SICAF SIF S.A. - GG Strategic · CIK 0001814890 · 10% owner

GG 1978 SICAF SIF S.A. · CIK 0001814891 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 21,926,170

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.32 to $42.06 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.nature: Reflects securities held directly by GG 1978 SICAF SIF S.A. - GG Strategic ("GG Strategic").

F2 · ownership.nature: GG Strategic is a sub-fund managed and administered by GG 1978 SICAF S.A. ("GG 1978 SICAF"). A board of directors consisting of Giammaria Giuliani, Achille G. Severgnini, Marco Sterzi and Franco Toscano has voting and dispositive power over the securities managed by GG 1978 SICAF. Each member of the board disclaims beneficial ownership over such shares. GG 1978 SICAF is owned by the GG Trust, of which Giammaria Giuliani is the beneficiary. The GG Trust is the 100% economic owner of the shares held by GG Strategic. Giammaria Giuliani disclaims beneficial ownership over the shares beneficially owned by GG Strategic. The trustee of the GG Trust is GISEV Trustees Limited. The protector of the GG Trust is Achille G. Severgnini, who has the power to remove and replace the trustee of the GG Trust.

F3 · ownership.nature: Each of the Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the direct holder to the extent of its direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein or are subject to Section 16.

SEC source: 0001140361-22-034012 · form4.xml · nonDerivative · entry 1

Giuliani Mario Germano · CIK 0001814882 · Director · 10% owner

MGG Strategic SICAF SIF S.A. - MGG Strategic · CIK 0001814889 · 10% owner

MGG Strategic SICAF SIF S.A. · CIK 0001922189 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 22,890,000

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.325 to $42.06 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.nature: Reflects securities held directly by MGG Strategic SICAF SIF S.A. - MGG Strategic, a Luxembourg company ("MGG Strategic"). MGG Strategic is a sub-fund managed and administered by MGG Strategic SICAF SIF S.A. ("MGG SICAF"). A board of directors consisting of M. Germano Giuliani, Achille G. Severgnini, Marco Sterzi and Franco Toscano has voting and dispositive power over the securities managed by MGG SICAF. Each member of the board disclaims beneficial ownership over such shares. MGG SICAF is owned by the MGG Trust of which M. Germano Giuliani is the beneficiary. The MGG Trust is the 100% economic owner of the shares held by MGG Strategic. M. Germano Giuliani disclaims beneficial ownership over the shares beneficially owned by MGG Strategic. The trustee of the MGG Trust is GISEV Trustees Limited. The protector of the MGG Trust is Achille G. Severgnini, who has the power to remove and replace the trustee of the MGG Trust.

F2 · ownership.nature: Each of the Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the direct holder to the extent of its direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein or are subject to Section 16.

SEC source: 0001209191-22-050172 · doc4.xml · nonDerivative · entry 2

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 276,712

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.08 to $42.51 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001140361-22-033641 · form4.xml · nonDerivative · entry 2

GG 1978 SICAF SIF S.A. · CIK 0001814891 · 10% owner

GG 1978 SICAF SIF S.A. - GG Strategic · CIK 0001814890 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 22,081,156

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.08 to $42.65 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.nature: Reflects securities held directly by GG 1978 SICAF SIF S.A. - GG Strategic (formerly known as Nogra Group SICAF SIF GG Strategic) ("GG Strategic").

F2 · ownership.nature: GG Strategic is a sub-fund managed and administered by GG 1978 SICAF S.A. ("GG 1978 SICAF"). A board of directors consisting of Giammaria Giuliani, Achille G. Severgnini, Marco Sterzi and Franco Toscano has voting and dispositive power over the securities managed by GG 1978 SICAF. Each member of the board disclaims beneficial ownership over such shares. GG 1978 SICAF is owned by the GG Trust, of which Giammaria Giuliani is the beneficiary. The GG Trust is the 100% economic owner of the shares held by GG Strategic. Giammaria Giuliani disclaims beneficial ownership over the shares beneficially owned by GG Strategic. The trustee of the GG Trust is GISEV Trustees Limited. The protector of the GG Trust is Achille G. Severgnini, who has the power to remove and replace the trustee of the GG Trust.

F3 · ownership.nature: Each of the Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the direct holder to the extent of its direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein or are subject to Section 16.

SEC source: 0001140361-22-033647 · form4.xml · nonDerivative · entry 2

Giuliani Mario Germano · CIK 0001814882 · Director · 10% owner

MGG Strategic SICAF SIF S.A. · CIK 0001922189 · 10% owner

MGG Strategic SICAF SIF S.A. - MGG Strategic · CIK 0001814889 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 23,044,986

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.08 to $42.625 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.nature: Reflects securities held directly by MGG Strategic SICAF SIF S.A. - MGG Strategic, a Luxembourg company ("MGG Strategic"). MGG Strategic is a sub-fund managed and administered by MGG Strategic SICAF SIF S.A. ("MGG SICAF"). A board of directors consisting of M. Germano Giuliani, Achille G. Severgnini, Marco Sterzi and Franco Toscano has voting and dispositive power over the securities managed by MGG SICAF. Each member of the board disclaims beneficial ownership over such shares. MGG SICAF is owned by the MGG Trust of which M. Germano Giuliani is the beneficiary. The MGG Trust is the 100% economic owner of the shares held by MGG Strategic. M. Germano Giuliani disclaims beneficial ownership over the shares beneficially owned by MGG Strategic. The trustee of the MGG Trust is GISEV Trustees Limited. The protector of the MGG Trust is Achille G. Severgnini, who has the power to remove and replace the trustee of the MGG Trust.

F2 · ownership.nature: Each of the Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the direct holder to the extent of its direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein or are subject to Section 16.

SEC source: 0001209191-22-050172 · doc4.xml · nonDerivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 328,737

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.28 to $42.57 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001140361-22-033641 · form4.xml · nonDerivative · entry 1

GG 1978 SICAF SIF S.A. · CIK 0001814891 · 10% owner

GG 1978 SICAF SIF S.A. - GG Strategic · CIK 0001814890 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 22,235,310

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.275 to $42.88 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.nature: Reflects securities held directly by GG 1978 SICAF SIF S.A. - GG Strategic (formerly known as Nogra Group SICAF SIF GG Strategic) ("GG Strategic").

F2 · ownership.nature: GG Strategic is a sub-fund managed and administered by GG 1978 SICAF S.A. ("GG 1978 SICAF"). A board of directors consisting of Giammaria Giuliani, Achille G. Severgnini, Marco Sterzi and Franco Toscano has voting and dispositive power over the securities managed by GG 1978 SICAF. Each member of the board disclaims beneficial ownership over such shares. GG 1978 SICAF is owned by the GG Trust, of which Giammaria Giuliani is the beneficiary. The GG Trust is the 100% economic owner of the shares held by GG Strategic. Giammaria Giuliani disclaims beneficial ownership over the shares beneficially owned by GG Strategic. The trustee of the GG Trust is GISEV Trustees Limited. The protector of the GG Trust is Achille G. Severgnini, who has the power to remove and replace the trustee of the GG Trust.

F3 · ownership.nature: Each of the Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the direct holder to the extent of its direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein or are subject to Section 16.

SEC source: 0001140361-22-033647 · form4.xml · nonDerivative · entry 1

Giuliani Mario Germano · CIK 0001814882 · Director · 10% owner

MGG Strategic SICAF SIF S.A. · CIK 0001922189 · 10% owner

MGG Strategic SICAF SIF S.A. - MGG Strategic · CIK 0001814889 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 23,199,140

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.275 to $42.87 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.nature: Reflects securities held directly by MGG Strategic SICAF SIF S.A. - MGG Strategic, a Luxembourg company ("MGG Strategic"). MGG Strategic is a sub-fund managed and administered by MGG Strategic SICAF SIF S.A. ("MGG SICAF"). A board of directors consisting of M. Germano Giuliani, Achille G. Severgnini, Marco Sterzi and Franco Toscano has voting and dispositive power over the securities managed by MGG SICAF. Each member of the board disclaims beneficial ownership over such shares. MGG SICAF is owned by the MGG Trust of which M. Germano Giuliani is the beneficiary. The MGG Trust is the 100% economic owner of the shares held by MGG Strategic. M. Germano Giuliani disclaims beneficial ownership over the shares beneficially owned by MGG Strategic. The trustee of the MGG Trust is GISEV Trustees Limited. The protector of the MGG Trust is Achille G. Severgnini, who has the power to remove and replace the trustee of the MGG Trust.

F2 · ownership.nature: Each of the Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the direct holder to the extent of its direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein or are subject to Section 16.

SEC source: 0001140361-22-032905 · form4.xml · nonDerivative · entry 2

GG 1978 SICAF SIF S.A. - GG Strategic · CIK 0001814890 · 10% owner

GG 1978 SICAF SIF S.A. · CIK 0001814891 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 22,426,170

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.395 to $43.155 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.nature: Reflects securities held directly by GG 1978 SICAF SIF S.A. - GG Strategic (formerly known as Nogra Group SICAF SIF GG Strategic) ("GG Strategic").

F2 · ownership.nature: GG Strategic is a sub-fund managed and administered by GG 1978 SICAF S.A. ("GG 1978 SICAF"). A board of directors consisting of Giammaria Giuliani, Achille G. Severgnini, Marco Sterzi and Franco Toscano has voting and dispositive power over the securities managed by GG 1978 SICAF. Each member of the board disclaims beneficial ownership over such shares. GG 1978 SICAF is owned by the GG Trust, of which Giammaria Giuliani is the beneficiary. The GG Trust is the 100% economic owner of the shares held by GG Strategic. Giammaria Giuliani disclaims beneficial ownership over the shares beneficially owned by GG Strategic. The trustee of the GG Trust is GISEV Trustees Limited. The protector of each of the GG Trust is Achille G. Severgnini, who has the power to remove and replace the trustee of the GG Trust.

F3 · ownership.nature: Each of the Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the direct holder to the extent of its direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein or are subject to Section 16.

SEC source: 0001140361-22-032906 · form4.xml · nonDerivative · entry 2

Giuliani Mario Germano · CIK 0001814882 · Director · 10% owner

Skyeline Management Ltd · CIK 0001814877 · 10% owner

Avara Management Ltd · CIK 0001814934 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 8,577,140

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.37 to $43.14 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.nature: Reflects securities held directly by Skyeline Management Ltd.

F2 · ownership.nature: Skyeline Management Ltd is wholly-owned by Avara Management Ltd. Avara Management Ltd is wholly-owned by M. Germano Giuliani.

F3 · ownership.nature: Each of the Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the direct holder to the extent of its direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein or are subject to Section 16.

SEC source: 0001140361-22-032905 · form4.xml · nonDerivative · entry 1

GG 1978 SICAF SIF S.A. - GG Strategic · CIK 0001814890 · 10% owner

GG 1978 SICAF SIF S.A. · CIK 0001814891 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 22,674,176

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.09 to $42.83 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.nature: Reflects securities held directly by GG 1978 SICAF SIF S.A. - GG Strategic (formerly known as Nogra Group SICAF SIF GG Strategic) ("GG Strategic").

F2 · ownership.nature: GG Strategic is a sub-fund managed and administered by GG 1978 SICAF S.A. ("GG 1978 SICAF"). A board of directors consisting of Giammaria Giuliani, Achille G. Severgnini, Marco Sterzi and Franco Toscano has voting and dispositive power over the securities managed by GG 1978 SICAF. Each member of the board disclaims beneficial ownership over such shares. GG 1978 SICAF is owned by the GG Trust, of which Giammaria Giuliani is the beneficiary. The GG Trust is the 100% economic owner of the shares held by GG Strategic. Giammaria Giuliani disclaims beneficial ownership over the shares beneficially owned by GG Strategic. The trustee of the GG Trust is GISEV Trustees Limited. The protector of each of the GG Trust is Achille G. Severgnini, who has the power to remove and replace the trustee of the GG Trust.

F3 · ownership.nature: Each of the Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the direct holder to the extent of its direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein or are subject to Section 16.

SEC source: 0001140361-22-032906 · form4.xml · nonDerivative · entry 1

Giuliani Mario Germano · CIK 0001814882 · Director · 10% owner

Skyeline Management Ltd · CIK 0001814877 · 10% owner

Avara Management Ltd · CIK 0001814934 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 8,814,759

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.24 to $42.83 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.nature: Reflects securities held directly by Skyeline Management Ltd.

F2 · ownership.nature: Skyeline Management Ltd is wholly-owned by Avara Management Ltd. Avara Management Ltd is wholly-owned by M. Germano Giuliani.

F3 · ownership.nature: Each of the Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the direct holder to the extent of its direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein or are subject to Section 16.

SEC source: 0001140361-22-031350 · form4.xml · nonDerivative · entry 1

GG 1978 SICAF SIF S.A. - GG Strategic · CIK 0001814890 · 10% owner

GG 1978 SICAF SIF S.A. · CIK 0001814891 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 22,924,176

F1 · ownership.nature: Reflects securities held directly by GG 1978 SICAF SIF S.A. - GG Strategic (formerly known as Nogra Group SICAF SIF GG Strategic) ("GG Strategic").

F2 · ownership.nature: GG Strategic is a sub-fund managed and administered by GG 1978 SICAF S.A. ("GG 1978 SICAF"). A board of directors consisting of Giammaria Giuliani, Achille G. Severgnini, Marco Sterzi and Franco Toscano has voting and dispositive power over the securities managed by GG 1978 SICAF. Each member of the board disclaims beneficial ownership over such shares. GG 1978 SICAF is owned by the GG Trust, of which Giammaria Giuliani is the beneficiary. The GG Trust is the 100% economic owner of the shares held by GG Strategic. Giammaria Giuliani disclaims beneficial ownership over the shares beneficially owned by GG Strategic. The trustee of the GG Trust is GISEV Trustees Limited. The protector of each of the GG Trust is Achille G. Severgnini, who has the power to remove and replace the trustee of the GG Trust.

F3 · ownership.nature: Each of the Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the direct holder to the extent of its direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein or are subject to Section 16.

SEC source: 0001140361-22-031349 · form4.xml · nonDerivative · entry 1

Giuliani Mario Germano · CIK 0001814882 · Director · 10% owner

Skyeline Management Ltd · CIK 0001814877 · 10% owner

Avara Management Ltd · CIK 0001814934 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 9,076,640

F1 · ownership.nature: Reflects securities held directly by Skyeline Management Ltd.

F2 · ownership.nature: Skyeline Management Ltd is wholly-owned by Avara Management Ltd. Avara Management Ltd is wholly-owned by M. Germano Giuliani.

F3 · ownership.nature: Each of the Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the direct holder to the extent of its direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein or are subject to Section 16.

SEC source: 0001209191-22-051637 · doc4.xml · derivative · entry 3

Reddoch James F. · CIK 0001814872 · EVP & Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Reddoch RPI LLC

Disclosed balance after: 478,870

Underlying: Class A Ordinary Shares · 24,000 shares

Expires not disclosed

F2 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange.

F3 · kind: The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold.

F4 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F4 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F5 · balance_after: The Reporting Person has agreed to retain and not sell 478,870 RPI US LP Interests convertible into 4,788,700 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances.

SEC source: 0001209191-22-056677 · doc4.xml · derivative · entry 7

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 58,890 shares

Expires not disclosed

F4 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange.

F5 · kind: The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold.

F6 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F6 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

SEC source: 0001209191-23-008556 · doc5.xml · derivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Legorreta Investments LLC

Disclosed balance after: 2,700,000

Underlying: Class A Ordinary Shares · 1,506,400 shares

Expires not disclosed

F1 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange.

F2 · kind: The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold.

F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F4 · balance_after: The Reporting Person has agreed to retain and not sell 5,103,392 RPI US LP Interests convertible into 51,033,928 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances.

SEC source: 0001209191-22-045451 · doc4.xml · nonDerivative · entry 2

Lloyd George W. · CIK 0001814899 · EVP, Investments & GC

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 201,114

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.90 to $44.01 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-045451 · doc4.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & GC

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 210,109

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.90 to $43.95 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-22-028395 · doc4.xml · nonDerivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 376,712

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.66 to $43.80 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-22-027643 · doc4.xml · nonDerivative · entry 1

Coyne Terrance P. · CIK 0001814876 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Indirect · By TPC RP 2021, LLC

Disclosed balance after: 970,000

F1 · kind: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.47 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.47 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-043689 · doc4.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & GC

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 221,968

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.91 to $44.01 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-043286 · doc4.xml · nonDerivative · entry 6

Lloyd George W. · CIK 0001814899 · EVP, Investments & GC

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 226,014

SEC source: 0001209191-22-043286 · doc4.xml · nonDerivative · entry 5

Lloyd George W. · CIK 0001814899 · EVP, Investments & GC

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 380,000

F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.70 to $43.89 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-043286 · doc4.xml · nonDerivative · entry 4

Lloyd George W. · CIK 0001814899 · EVP, Investments & GC

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 226,114

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.93 to $43.35 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-043286 · doc4.xml · nonDerivative · entry 3

Lloyd George W. · CIK 0001814899 · EVP, Investments & GC

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 405,000

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.91 to $43.13 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-043282 · doc4.xml · nonDerivative · entry 2

Urist Marshall · CIK 0001838139 · EVP, Research & Investments

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.38 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-043286 · doc4.xml · nonDerivative · entry 2

Lloyd George W. · CIK 0001814899 · EVP, Investments & GC

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 228,886

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.90 to $43.17 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-043286 · doc4.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & GC

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 410,443

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.72 to $43.16 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-043282 · doc4.xml · nonDerivative · entry 1

Urist Marshall · CIK 0001838139 · EVP, Research & Investments

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,734

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.18 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-22-041846 · doc4.xml · nonDerivative · entry 1

HODGSON DAVID C · CIK 0001193346 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,674

F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.